Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease

被引:4
|
作者
Watase, Mayuko [1 ]
Mochimaru, Takao [1 ,2 ]
Kawase, Honomi [1 ]
Shinohara, Hiroyuki [1 ]
Sagawa, Shinobu [1 ]
Ikeda, Toshiki [1 ]
Yagi, Shota [1 ]
Yamamura, Hiroyuki [1 ]
Matsuyama, Emiko [1 ]
Kaji, Masanori [1 ]
Kurihara, Momoko [1 ]
Sato, Midori [1 ]
Horiuchi, Kohei [1 ]
Watanabe, Risa [1 ]
Nukaga, Shigenari [1 ]
Irisa, Kaoru [1 ]
Satomi, Ryosuke [1 ]
Oyamada, Yoshitaka [1 ,2 ]
机构
[1] Natl Hosp Org Tokyo Med Ctr, Dept Resp Med, Tokyo, Japan
[2] Natl Hosp Org Tokyo Med Ctr, Dept Allergy, Tokyo, Japan
来源
PLOS ONE | 2023年 / 18卷 / 03期
关键词
PULMONARY-FIBROSIS;
D O I
10.1371/journal.pone.0283288
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
No biomarkers have been identified in bronchoalveolar lavage fluid (BALF) for predicting fibrosis progression or prognosis in progressive fibrosing interstitial lung disease (PF-ILD). We investigated BALF biomarkers for PF-ILD diagnosis and prognosis assessment. Overall, 120 patients with interstitial pneumonia who could be diagnosed with PF-ILD or non PF-ILD were enrolled in this retrospective study. PF-ILD was diagnosed according to Cottin's definition. All patients underwent bronchoscopy and BALF collection. We evaluated blood and BALF parameters, high-resolution computed tomography (HRCT) patterns, and spirometry data to identify factors influencing PF-ILD diagnosis and prognosis. On univariate logistic analysis, age, sex, the BALF white blood cell fraction (neutrophil, lymphocyte, eosinophil, and neutrophil-to-lymphocyte ratio), BALF flow cytometric analysis (CD8), and an idiopathic pulmonary fibrosis/usual interstitial pneumonia pattern on HRCT were correlated with PF-ILD diagnosis. Multivariate logistic regression analysis revealed that sex (male), age (cut-off 62 years, area under the curve [AUC] 0.67; sensitivity 0.80; specificity 0.47), white blood cell fraction in BALF (NLR, neutrophil, and lymphocyte), and CD8 in BALF (cut-off 34.2; AUC 0.66; sensitivity, 0.74; specificity, 0.62) were independent diagnostic predictors for PF-ILD. In BALF, the NLR (cut-off 8.70, AUC 0.62; sensitivity 0.62; specificity 0.70), neutrophil count (cut-off 3.0, AUC 0.59; sensitivity 0.57; specificity 0.63), and lymphocyte count (cut-off 42.0, AUC 0.63; sensitivity 0.77; specificity 0.53) were independent diagnostic predictors. In PF-ILD patients (n = 77), lactate dehydrogenase (cut-off 275, AUC 0.69; sensitivity 0.57; specificity 0.78), Krebs von den Lungen-6 (cut-off 1,140, AUC 0.74; sensitivity 0.71; specificity 0.76), baseline forced vital capacity (FVC) (cut-off 1.75 L, AUC 0.71; sensitivity, 0.93; specificity, 0.46), and BALF neutrophil ratio (cut-off 6.0, AUC 0.72; sensitivity 0.79; specificity 0.80) correlated with death within 3 years. The BALF cellular ratio, particularly the neutrophil ratio, correlated with the diagnosis and prognosis of PF-ILD. These findings may be useful in the management of patients with interstitial pneumonia.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease
    Charlisa D. Gibson
    Matthias C. Kugler
    Himanshu Deshwal
    John S. Munger
    Rany Condos
    Lung, 2020, 198 : 597 - 608
  • [22] Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies
    Wongkarnjana, Amornpun
    Scallan, Ciaran
    Kolb, Martin R. J.
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (05) : 436 - 442
  • [23] The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease
    Sarkar, Paroma
    Avram, Cristina
    Chaudhuri, Nazia
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (10) : 1001 - 1008
  • [24] The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease
    Swigris, Jeffrey
    Cutts, Katelyn
    Male, Natalia
    Baldwin, Michael
    Rohr, Klaus B.
    Bushnell, Donald M.
    ERJ OPEN RESEARCH, 2021, 7 (02)
  • [25] PREVALENCE OF FIBROSING PROGRESSIVE INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS PATIENTS
    Manfredi, A.
    Venerito, V.
    Cazzato, M.
    Gentileschi, S.
    La Corte, L.
    Iuliano, A. M.
    Cassone, G.
    Vacchi, C.
    Tomassini, C.
    Rai, A.
    Lavista, M.
    Andrisani, D.
    Laurino, E.
    Canofari, C.
    Pedrollo, E.
    Atzeni, F.
    Sebastiani, D.
    Frediani, B.
    Mosca, M.
    Iannone, F.
    Sebastiani, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 845 - 846
  • [26] Progressive fibrosing interstitial lung disease in rheumatoid arthritis: A retrospective study
    Denis, Anna
    Henket, Monique
    Ernst, Marie
    Maes, Nathalie
    Thys, Marie
    Regnier, Celine
    Malaise, Olivier
    Frix, Anne-Noelle
    Gester, Fanny
    Desir, Colin
    Meunier, Paul
    Louis, Renaud
    Malaise, Michel
    Guiot, Julien
    FRONTIERS IN MEDICINE, 2022, 9
  • [27] Editorial: Progressive fibrosing interstitial lung disease: from bench to bedside
    Guiot, Julien
    Njock, Makon-Sebastien
    FRONTIERS IN MEDICINE, 2023, 10
  • [28] Efficacy of Antifibrotic Treatments in Patients with Progressive Fibrosing Interstitial Lung Disease
    Sugino, K.
    Ono, H.
    Saito, M.
    Ando, M.
    Tsuboi, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [29] Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
    Aryeh Fischer
    Jörg Distler
    Clinical Rheumatology, 2019, 38 : 2673 - 2681
  • [30] Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline
    Nagy, Alexandra
    Nagy, Tamas
    Kolonics-Farkas, Abigel Margit
    Eszes, Noemi
    Vincze, Krisztina
    Barczi, Eniko
    Tarnoki, Adam Domonkos
    Tarnoki, David Laszlo
    Nagy, Gyorgy
    Kiss, Emese
    Maurovich-Horvat, Pal
    Bohacs, Aniko
    Muller, Veronika
    FRONTIERS IN PHARMACOLOGY, 2021, 12